Please assess the completion status of the following clinical trial:

Trial Title: Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged 18 years and over~2. Planned surgical resection of NSCLC, stage IB ≥ 4 cm, II or IIIA according to the 8th edition of TNM classification16.~   1. Cohort #1: Neoadjuvant Therapy - For patients who will receive neoadjuvant therapy, enrollment occurs prior to the initiation of treatment. Patients undergoing neoadjuvant therapy who achieved tumor reduction, are eligible based on baseline radiographic staging.~  2. Cohort #2: Pre-Surgery - For patients identified prior to planned surgical resection, enrollment occurs within 30 days of the planned surgery. Eligibility is based on surgical pathology.~  3. Cohort #3: Post-Surgery - For patients identified post-surgical resection, enrollment occurs prior to the initiation of adjuvant therapy. Eligibility is based on surgical pathology.~3. Patients with positive margins and those requiring adjuvant radiation therapy are eligible.~4. Patients with a secondary malignancy that was treated with curative intent and without evidence of relapse for at least 5 years.~5. Willingness to undergo all study collection procedures and follow up.~6. Provision of written informed consent~Exclusion Criteria:~1. Male or female aged less than 18 years~2. NSCLC disease other than stated above~3. Patients with a secondary malignancy that was not treated with curative intent or has had a disease relapse in the past 5 years.~4. Unwilling to undergo all study collection procedures and follow up.~5. Unable or unwilling to provide consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).